Edwards Lifesciences (EW) VP Catherine M. Szyman Sells 9,815 Shares

Edwards Lifesciences (NYSE:EW) VP Catherine M. Szyman sold 9,815 shares of the firm’s stock in a transaction on Thursday, May 24th. The shares were sold at an average price of $139.39, for a total transaction of $1,368,112.85. Following the transaction, the vice president now directly owns 20,012 shares of the company’s stock, valued at $2,789,472.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of Edwards Lifesciences traded down $2.10, reaching $135.47, on Friday, MarketBeat Ratings reports. The company’s stock had a trading volume of 39,790 shares, compared to its average volume of 1,214,815. Edwards Lifesciences has a 52-week low of $100.20 and a 52-week high of $143.22. The stock has a market capitalization of $29.31 billion, a P/E ratio of 35.64, a PEG ratio of 2.04 and a beta of 0.64. The company has a quick ratio of 1.63, a current ratio of 2.07 and a debt-to-equity ratio of 0.14.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, April 24th. The medical research company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.11. Edwards Lifesciences had a net margin of 17.36% and a return on equity of 28.60%. The business had revenue of $938.00 million during the quarter, compared to analysts’ expectations of $936.69 million. During the same period last year, the company posted $0.94 EPS. The business’s revenue was up 6.2% on a year-over-year basis. analysts expect that Edwards Lifesciences will post 4.61 earnings per share for the current year.

EW has been the subject of several research analyst reports. Guggenheim reaffirmed a “buy” rating and set a $162.00 target price on shares of Edwards Lifesciences in a research note on Friday, February 2nd. Stifel Nicolaus reaffirmed a “buy” rating and set a $155.00 target price on shares of Edwards Lifesciences in a research note on Friday, February 2nd. Canaccord Genuity reaffirmed a “buy” rating and set a $174.00 target price (up from $140.00) on shares of Edwards Lifesciences in a research note on Friday, February 2nd. Cowen reaffirmed a “buy” rating and set a $150.00 target price on shares of Edwards Lifesciences in a research note on Thursday, February 1st. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $150.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, January 31st. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Edwards Lifesciences presently has an average rating of “Buy” and an average target price of $148.87.

Large investors have recently modified their holdings of the business. BB&T Securities LLC grew its stake in shares of Edwards Lifesciences by 87.4% in the 4th quarter. BB&T Securities LLC now owns 11,991 shares of the medical research company’s stock worth $1,351,000 after buying an additional 5,593 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Edwards Lifesciences by 2.2% in the 4th quarter. BlackRock Inc. now owns 15,410,737 shares of the medical research company’s stock worth $1,736,943,000 after acquiring an additional 331,896 shares during the last quarter. D.A. Davidson & CO. lifted its holdings in shares of Edwards Lifesciences by 8.2% in the 4th quarter. D.A. Davidson & CO. now owns 24,397 shares of the medical research company’s stock worth $2,750,000 after acquiring an additional 1,842 shares during the last quarter. Macquarie Group Ltd. lifted its holdings in shares of Edwards Lifesciences by 0.9% in the 4th quarter. Macquarie Group Ltd. now owns 69,963 shares of the medical research company’s stock worth $7,768,000 after acquiring an additional 624 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its holdings in shares of Edwards Lifesciences by 9.1% in the 1st quarter. Teacher Retirement System of Texas now owns 98,385 shares of the medical research company’s stock worth $13,727,000 after acquiring an additional 8,195 shares during the last quarter. 81.03% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply